Plain-English translation of NCT07215234 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing a new treatment called , which is injected directly into the eye as a one-time dose. Researchers want to see if this medication can slow or stop the progression of geographic atrophy, a condition where the light-sensitive cells in the center of your vision gradually break down, leading to vision loss over time.
Geographic atrophy is a serious complication of age-related macular degeneration that currently has very limited treatment options. This study exists to find out whether this new medication can help protect your remaining vision and prevent further decline.
You likely qualify if…
You likely don't qualify if…
You will receive one injection of the study medication (or a sham procedure if you're in the comparison group) directly into your eye. The trial lasts approximately 2 years of active monitoring, followed by an additional 3 years of extended follow-up visits. During this time, you'll return for regular eye exams and imaging tests to track how the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States